Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Clinical trial NCT07374614 · RECRUITING

Trial details

NCT number: NCT07374614
Sponsor: Peking University Shenzhen Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Non-Small Cell Lung Cancer ALK Iruplinalkib Lorlatinib Real-world Study Observational Study

Start date: 2026-01-31
Primary completion: 2028-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.